Agonist
Back to library
GLP-1Oral

Orforglipron

Also known as: LY3502970 · OWL833

Non-peptide oral small-molecule GLP-1 receptor agonist. Acts at the same receptor as semaglutide but is small enough to be absorbed without absorption enhancers, and is not a substrate for GI peptidases.

At a glance

Half-life
29 hours
Common route
Oral
Typical dose range
3,000–45,000mcg
Stability (reconstituted)
60days refrigerated

Best timing

Once daily, no food or fluid restrictions (unlike Rybelsus). Most trials dose morning.

Contraindications

  • Personal or family history of medullary thyroid carcinoma
  • Multiple endocrine neoplasia syndrome type 2
  • History of pancreatitis
  • Severe GI disease
  • Pregnancy

Watch symptoms

  • Nausea, vomiting (titration-dependent)
  • Constipation or diarrhea
  • Elevated liver enzymes in subset
  • Resting heart rate increase
  • Decreased appetite

Citations

The primary literature.

  1. 01Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity (ATTAIN-1)PubMed
  2. 02Efficacy and safety of orforglipron in adults with type 2 diabetesPubMed
Back to library